269 related articles for article (PubMed ID: 21859492)
21. Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.
Sun A; Tang J; Hong Y; Song J; Terranova PF; Thrasher JB; Svojanovsky S; Wang HG; Li B
Prostate; 2008 Mar; 68(4):453-61. PubMed ID: 18196538
[TBL] [Abstract][Full Text] [Related]
22. 5alpha-androstane-3alpha,17beta-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression.
Yang Q; Titus MA; Fung KM; Lin HK
J Cell Biochem; 2008 Aug; 104(5):1612-24. PubMed ID: 18320593
[TBL] [Abstract][Full Text] [Related]
23. Exploiting AR-Regulated Drug Transport to Induce Sensitivity to the Survivin Inhibitor YM155.
Nyquist MD; Corella A; Burns J; Coleman I; Gao S; Tharakan R; Riggan L; Cai C; Corey E; Nelson PS; Mostaghel EA
Mol Cancer Res; 2017 May; 15(5):521-531. PubMed ID: 28465296
[TBL] [Abstract][Full Text] [Related]
24. Combination of carmustine and selenite effectively inhibits tumor growth by targeting androgen receptor, androgen receptor-variants, and Akt in preclinical models: New hope for patients with castration resistant prostate cancer.
Thamilselvan V; Menon M; Thamilselvan S
Int J Cancer; 2016 Oct; 139(7):1632-47. PubMed ID: 27198552
[TBL] [Abstract][Full Text] [Related]
25. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
26. A natural molecule, urolithin A, downregulates androgen receptor activation and suppresses growth of prostate cancer.
Dahiya NR; Chandrasekaran B; Kolluru V; Ankem M; Damodaran C; Vadhanam MV
Mol Carcinog; 2018 Oct; 57(10):1332-1341. PubMed ID: 30069922
[TBL] [Abstract][Full Text] [Related]
27. Galbanic acid decreases androgen receptor abundance and signaling and induces G1 arrest in prostate cancer cells.
Zhang Y; Kim KH; Zhang W; Guo Y; Kim SH; Lü J
Int J Cancer; 2012 Jan; 130(1):200-12. PubMed ID: 21328348
[TBL] [Abstract][Full Text] [Related]
28. Effect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.
Wang S; Wu J; Suburu J; Gu Z; Cai J; Axanova LS; Cramer SD; Thomas MJ; Perry DL; Edwards IJ; Mucci LA; Sinnott JA; Loda MF; Sui G; Berquin IM; Chen YQ
Carcinogenesis; 2012 Feb; 33(2):404-12. PubMed ID: 22159221
[TBL] [Abstract][Full Text] [Related]
29. Modulation of protein phosphatase 2A activity alters androgen-independent growth of prostate cancer cells: therapeutic implications.
Bhardwaj A; Singh S; Srivastava SK; Honkanen RE; Reed E; Singh AP
Mol Cancer Ther; 2011 May; 10(5):720-31. PubMed ID: 21393425
[TBL] [Abstract][Full Text] [Related]
30. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
31. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
[TBL] [Abstract][Full Text] [Related]
32. Manipulating prohibitin levels provides evidence for an in vivo role in androgen regulation of prostate tumours.
Dart DA; Spencer-Dene B; Gamble SC; Waxman J; Bevan CL
Endocr Relat Cancer; 2009 Dec; 16(4):1157-69. PubMed ID: 19635783
[TBL] [Abstract][Full Text] [Related]
33. Conversion of androgen receptor signaling from a growth suppressor in normal prostate epithelial cells to an oncogene in prostate cancer cells involves a gain of function in c-Myc regulation.
Vander Griend DJ; Litvinov IV; Isaacs JT
Int J Biol Sci; 2014; 10(6):627-42. PubMed ID: 24948876
[TBL] [Abstract][Full Text] [Related]
34. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.
Kokontis JM; Hay N; Liao S
Mol Endocrinol; 1998 Jul; 12(7):941-53. PubMed ID: 9658399
[TBL] [Abstract][Full Text] [Related]
35. An AR-Skp2 pathway for proliferation of androgen-dependent prostate-cancer cells.
Wang H; Sun D; Ji P; Mohler J; Zhu L
J Cell Sci; 2008 Aug; 121(Pt 15):2578-87. PubMed ID: 18628304
[TBL] [Abstract][Full Text] [Related]
36. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
37. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens.
Waltering KK; Helenius MA; Sahu B; Manni V; Linja MJ; Jänne OA; Visakorpi T
Cancer Res; 2009 Oct; 69(20):8141-9. PubMed ID: 19808968
[TBL] [Abstract][Full Text] [Related]
38. Cryptotanshinone suppresses androgen receptor-mediated growth in androgen dependent and castration resistant prostate cancer cells.
Xu D; Lin TH; Li S; Da J; Wen XQ; Ding J; Chang C; Yeh S
Cancer Lett; 2012 Mar; 316(1):11-22. PubMed ID: 22154085
[TBL] [Abstract][Full Text] [Related]
39. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
[TBL] [Abstract][Full Text] [Related]
40. Neural protein gamma-synuclein interacting with androgen receptor promotes human prostate cancer progression.
Chen J; Jiao L; Xu C; Yu Y; Zhang Z; Chang Z; Deng Z; Sun Y
BMC Cancer; 2012 Dec; 12():593. PubMed ID: 23231703
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
